This trial will study the effects of vancomycin on biliary atresia and primary sclerosing cholangitis. It will also study the microbiome of the intestine and its interactions with the human host.
1 Primary · 0 Secondary · Reporting Duration: 3 months
200 Total Participants · 1 Treatment Group
Primary Treatment: Oral Vancomycin · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 2 - 40 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: